These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 29325180)

  • 1. Sertindole: EEG Analysis, Tolerability, and Clinical Efficacy.
    Kroc A; Dębicka M; Wierzbicka A; Wołkow L; Jernajczyk W; Wichniak A
    Pharmacopsychiatry; 2018 Jul; 51(4):144-147. PubMed ID: 29325180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
    Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
    Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance.
    Pezawas L; Quiner S; Moertl D; Tauscher J; Barnas C; Küfferle B; Wolf R; Kasper S
    Int Clin Psychopharmacol; 2000 Jul; 15(4):207-14. PubMed ID: 10954060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daytime sleepiness and EEG abnormalities in patients treated with second generation antipsychotic agents.
    Okruszek L; Jernajczyk W; Wierzbicka A; Waliniowska E; Jakubczyk T; Jarema M; Wichniak A
    Pharmacol Rep; 2014 Dec; 66(6):1077-82. PubMed ID: 25443738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of sertindole in schizophrenia: a clinical review.
    Zoccali RA; Bruno A; Muscatello MR
    J Clin Psychopharmacol; 2015 Jun; 35(3):286-95. PubMed ID: 25830594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sertindole in schizophrenia: efficacy and safety issues.
    Muscatello MR; Bruno A; Micali Bellinghieri P; Pandolfo G; Zoccali RA
    Expert Opin Pharmacother; 2014 Sep; 15(13):1943-53. PubMed ID: 25084209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clozapine withdrawal symptoms after change to sertindole in a schizophrenic patient.
    Berecz R; Glaub T; Kellermann M; de la Rubia A; Llerena A; Degrell I
    Pharmacopsychiatry; 2000 Jan; 33(1):42-4. PubMed ID: 10721883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sertindole: a review of clinical efficacy.
    Kane JM
    Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S59-63; discussion S63-4. PubMed ID: 9690972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ejaculatory dysfunction in patient with schizophrenia on sertindole.
    Jukić MK; Drmić S; Mimica N
    Psychiatr Danub; 2010 Mar; 22(1):128-31. PubMed ID: 20305609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sertindole, a new atypical antipsychotic for the treatment of schizophrenia.
    Brown LA; Levin GM
    Pharmacotherapy; 1998; 18(1):69-83. PubMed ID: 9469684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sertindole: efficacy and safety in schizophrenia.
    Lindström E; Levander S
    Expert Opin Pharmacother; 2006 Sep; 7(13):1825-34. PubMed ID: 16925508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmenting clozapine with sertindole: a double-blind, randomized, placebo-controlled study.
    Nielsen J; Emborg C; Gydesen S; Dybbro J; Aagaard J; Haderup K; Glyngdal P; Fabricius S; Thode D; Lublin H; Andersen T; Damkier P; Taylor D
    J Clin Psychopharmacol; 2012 Apr; 32(2):173-8. PubMed ID: 22367659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug safety and efficacy evaluation of sertindole for schizophrenia.
    Karamatskos E; Lambert M; Mulert C; Naber D
    Expert Opin Drug Saf; 2012 Nov; 11(6):1047-62. PubMed ID: 22992213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sertindole : a review of its use in schizophrenia.
    Murdoch D; Keating GM
    CNS Drugs; 2006; 20(3):233-55. PubMed ID: 16529528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sertindole in the long-term treatment of schizophrenia.
    Hale AS; Azorin JM; Lemming OM; Mæhlum E
    Int Clin Psychopharmacol; 2012 Jul; 27(4):231-7. PubMed ID: 22609816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group.
    Daniel DG; Wozniak P; Mack RJ; McCarthy BG
    Psychopharmacol Bull; 1998; 34(1):61-9. PubMed ID: 9564200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of 12 weeks of treatment with sertindole or olanzapine in patients with chronic schizophrenia who did not respond successfully to their previous treatments: a randomized, double-blind, parallel-group, flexible-dose study.
    Kwon JS; Mittoux A; Hwang JY; Ong A; Cai ZJ; Su TP
    Int Clin Psychopharmacol; 2012 Nov; 27(6):326-35. PubMed ID: 22850268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The European post-marketing observational sertindole study: an investigation of the safety of antipsychotic drug treatment.
    Kasper S; Möller HJ; Hale A
    Eur Arch Psychiatry Clin Neurosci; 2010 Feb; 260(1):59-68. PubMed ID: 19455275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the safety and tolerability of sertindole.
    Hale AS
    Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S65-70. PubMed ID: 9690973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case histories illustrating the utility of sertindole in clinical practice.
    Schuck P; van den Ameele H; Jaanson P; Ryckmans V; Hawley C
    CNS Drugs; 2004; 18 Suppl 2():31-40; discussion 41-3. PubMed ID: 15461314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.